Table 1.
Baseline and COVID-19 related characteristics (N = 214).
| Age (years) | 59.58 (13.79) |
| Sex (male) | 154/214 (71.96) |
| Race | |
| Caucasian | 161/214 (75.23) |
| Hispanics | 48/214 (22.43) |
| Others | 5/214 (2.34) |
| Cardiovascular risk factors | |
| Hypertension | 113/214 (52.80) |
| Treatment with ACEI or ARB | 77/214 (35.98) |
| Dyslipidaemia | 94/214 (43.93) |
| Diabetes | 47/214 (21.96) |
| BMI (Kg/m2) | 30.88 (5.74) |
| Harmful alcohol intake | 21/214 (9.81) |
| Previous or active smoking | 49/214 (22.90) |
| Other comorbidities | |
| COPD | 16/214 (7.48) |
| Chronic kidney disease | 28/214 (13.08) |
| Charlson index | 1.90 (1.98) |
| Known history of liver disease | 16/214 (7.48) |
| Etiology | |
| Alcohol | 2/16 (12.50) |
| Hepatitis C | 2/16 (12.50) |
| MAFLD | 9/16 (56.25) |
| Others | 3/16 (18.75) |
| Severity of liver disease | |
| Mild fibrosis | 14/16 (87.50) |
| cACLD | 1/16 (6.25) |
| Decompensated liver disease | 1/16 (6.25) |
| Specific treatment for COVID-19 | |
| Lopinavir/ritonavir | 207/214 (96.73) |
| Hydroxychloroquine | 211/214 (98.60) |
| Remdesivir | 35/214 (16.36) |
| Beta-interferon | 96/214 (44.86) |
| Azithromycin | 97/214 (45.33) |
| Ceftriaxone | 167/214 (78.37) |
| Corticosteroids | 182/214 (85.05) |
| Tocilizumab | 166/214 (77.57) |
| Laboratory tests | |
| Before admission | |
| AST (U/L) | 29.43 (24.46) |
| ALT (U/L) | 31.51 (22.73) |
| Bilirubin (mg/dl) | 1.45 (10.41) |
| Albumin (g/dl) | 4.20 (0.58) |
| Platelet count (109/l) | 224.05 (66.07) |
| At admission | |
| AST (U/L) | 84.5 (80.86) |
| ALT (U/L) | 51.21 (36.28) |
| Bilirubin (mg/dl) | 0.78 (1.37) |
| Albumin (g/dl) | 3.85 (0.64) |
| Platelet count (109/l) | 199.82 (89.11) |
Data are expressed as mean (SD) or n (%).
ACEI, angiotensin converting enzyme inhibitors; ALT, alanine aminotransferase; ARB, angiotensin receptor blockers; AST, aspartate aminotransferase; BMI, body mass index; cACLD, compensated advanced chronic liver disease; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; MAFLD, metabolic associated liver disease; SD, standard deviation.